Advertisement


Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer

2024 SABCS

Advertisement

Sibylle Loibl, MD, PhD, of the German Breast Group, Neu-Isenburg, Germany, presented primary results of the randomized phase III PADMA trial comparing first-line endocrine therapy plus palbociclib vs standard mono-chemotherapy in women with high-risk HER2-negative/HR-positive metastatic breast cancer and indication for chemotherapy (Abstract LB1-03).  



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The PADMA study investigated whether an endocrine-based treatment with palbociclib is superior to mono chemotherapy as first-line treatment in hormone receptor-positive HER2-negative metastatic breast cancer patients. And the study enrolled 130 patients, 120 did start the treatment. And with this we could demonstrate that actually, indeed the hypothesis was true and the time to treatment failure as an endpoint, which included not only progression and death, but also stopping the treatment due to toxicity and patient's preference, could be improved with the endocrine-based treatment from 7.2 month to 17 months around. This was really a great improvement with a hazard rate of 0.45, which is really great. And this was highly statistically significant and clinically meaningful. Of course, we looked at more conventionally timed events endpoints like the progression-free survival, where we saw actually the main difference in favor of the endocrine-based treatment with palbociclib and patients in the mono chemotherapy arm just were progression-free for about seven months. Almost identical results, and also we saw that the overall survival tended to be longer with about 10 months longer for the patients on endocrine-based treatment. One cannot say that the mono chemotherapy arm was inferior because it was capecitabine and paclitaxel which is really the standard of care as mono chemotherapy. But with that, I think now we have the second study reporting those data in the first line metastatic breast cancer and I think now it confirms that chemotherapy has no role in patients with hormone receptor-positive, HER2-negative breast cancer. The standard of care is and remains an endocrine-based treatment for now with a CDK 4/6 inhibitor, but others will come. We have seen the now 120 data with a triplet combination for those who have an additional PI3K kinase mutation, and I think those data are all very supportive that we really can treat patients irrespective of the type of mutations with an endocrine-based treatment. Toxicity wise, we saw not many differences. What we saw before, of course, palbociclib comes with a higher rate of hematologic toxicity. The non-hematologic toxicity was equal in both arms. And capecitabine, as we know, has the main issue with diarrhea and hand-foot syndrome, which was more common there. In conclusion, chemotherapy is out as first-line treatment in metastatic breast cancer for hormone receptor positive HER2-negative breast cancer patients.

Related Videos

Breast Cancer

Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE

Mafalda Oliveira, MD, PhD, of Vall d’Hebron Institute of Oncology, Spain, presented the primary results of SOLTI VALENTINE, a neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor–positive/HER2-negative early breast cancer (Abstract LB1-06). 

Breast Cancer

Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis

Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy by pace of disease progression on prior endocrine-based therapy from DESTINY-Breast06 (Abstract LB1-04).

Breast Cancer

Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer

Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the impact of anthracyclines in high genomic risk node-negative HR-positive/HER2-negative breast cancer (Abstract GS3-03).

Breast Cancer

Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer

Andrew Tutt, MB ChB, PhD, FMedSci, Director of The Breast Cancer Now Toby Robins Research Centre and the Institute of Cancer Research (ICR) and Guy’s Hospital King’s College, London, discusses longer-term follow-up of OlympiA, a phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/BRCA2 pathogenic variants and high-risk HER2-negative primary breast cancer (Abstract GS1-09).

Breast Cancer

Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer

Adrienne Waks, MD, of Dana-Farber Cancer Institute, Boston, discusses the randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab vs paclitaxel/trastuzumab/pertuzumab in patients with stage II-III HER2-positive breast cancer. This trial is being done to determine how well HER2-positive breast cancer responds to preoperative treatment using one of two different combinations of drugs as a treatment for this diagnosis (Abstract LB1-02).

Advertisement

Advertisement




Advertisement